特立帕肽联合仙灵骨葆治疗骨质疏松的效果及对患者骨密度水平的影响
|
摘要
目的:探讨特立帕肽联合仙灵骨葆治疗骨质疏松的效果及对患者骨密度水平的影响。方法:选取骨质疏松症患者88例,按照随机数字表法,分为对照组(n=44)和观察组(n=44)。对照组采用特里帕肽进行治疗,观察组在对照组基础上,加用仙灵骨葆胶囊进行治疗,比较两组治疗前、治疗12周后及治疗24周后的骨密度水平、骨标志物变化情况、症状积分改善情况。结果:经过相应药物治疗后,观察组腰椎骨密度高于对照组,差异有统计学意义(P<0.05);观察组治疗后的血清骨钙素(sOC)和骨碱性磷酸酶(sBAP)高于对照组,差异有统计学意义(P<0.05);两组不良反应发生情况差异无统计学意义(P>0.05)。结论:特立帕肽联合仙灵骨葆治疗骨质疏松的效果显著,可有效提高患者的骨密度水平,安全性高,值得在临床上进一步推广应用。
Objective:To investigate the effects of Teriparatide combined Xianlinggubao treatment of osteoporosis and its effect on bone mineral density.Method:88 patients with osteoporosis were selected and divided into the control group(n=44) and the observation group(n=44) according to random number table method.The control group using the Teriparatide treatment,the observation group used Xianlinggubao capsule for treatment based on the control group,before and after treatment for 12 weeks and 24 weeks after treatment of bone density,bone markers,improvement of symptoms between the two groups were compared.Result:After treatment,the observation group of lumbar bone mineral density was higher than the control group,the difference was statistically significant(P<0.05), after treatment,the serum osteocalcin(sOC) and bone alkaline phosphatase(sBAP) in the observation group were higher than the control group,the differences were statistically significant(P<0.05),the incidence of adverse reactions of the two groups had no significant difference(P>0.05).Conclusion:Teriparatide combined Xianlinggubao treatment of osteoporosis has significant effect,can effectively improve the bone mineral density,high safety,worthy of further clinical application.
Objective:To investigate the effects of Teriparatide combined Xianlinggubao treatment of osteoporosis and its effect on bone mineral density.Method:88 patients with osteoporosis were selected and divided into the control group(n=44) and the observation group(n=44) according to random number table method.The control group using the Teriparatide treatment,the observation group used Xianlinggubao capsule for treatment based on the control group,before and after treatment for 12 weeks and 24 weeks after treatment of bone density,bone markers,improvement of symptoms between the two groups were compared.Result:After treatment,the observation group of lumbar bone mineral density was higher than the control group,the difference was statistically significant(P<0.05), after treatment,the serum osteocalcin(sOC) and bone alkaline phosphatase(sBAP) in the observation group were higher than the control group,the differences were statistically significant(P<0.05),the incidence of adverse reactions of the two groups had no significant difference(P>0.05).Conclusion:Teriparatide combined Xianlinggubao treatment of osteoporosis has significant effect,can effectively improve the bone mineral density,high safety,worthy of further clinical application.
引文
[1]张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识(第三稿,2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010.
[2]张宇,李新,张红梅,等.老年骨质疏松及伴有低钠血症骨质疏松患者的临床研究[J].中华老年医学杂志,2017,36(8):872-876.
[3]张春丽,李忠海,周颖,等.构建骨质疏松动物模型建模方法的改进及评价[J].中国组织工程研究,2016,20(5):754-759.
[4]杨卫红,俞洁菲,张琼,等.老年骨质疏松患者对骨质疏松认知程度和生活质量现况调查[J].中华老年医学杂志,2015,34(11):1254-1256.
[5]付秋瑞,刘海鹏,陈高飞,等.pkp结合抗骨质疏松药治疗骨质疏松性椎体压缩骨折效果探讨[J].中国生化药物杂志,2017,25(7):233-234.
[6]徐绍俊,黄建烽,邵敏,等.雌激素受体α基因甲基化与骨质疏松关系的研究进展[J].中国骨质疏松杂志,2017,23(3):388-391.
[7]杨德鸿,胡少宇,孟越,等.特立帕肽保守治疗骨质疏松性脊柱骨折:12例报告[J].南方医科大学学报,2016,36(3):414-418.
[8]骆天红,Julie Michelle Blair,Sebastian Sorsaburu等.特立帕肽(重组人甲状旁腺素1-34)在骨质疏松治疗中的应用[J].中华内分泌代谢杂志,2013,29(12):后插3-后插9.
[9]周晓清,陈晓钢,胡小吾等.特立帕肽预防骨质疏松患者腰椎融合术后椎弓根螺钉松动的前瞻性研究[J].中国骨质疏松杂志,2014,20(3):285-287,296.
[10]谢辉.联合使用固力康和特立帕肽对去卵巢大鼠股骨干骺端骨量、骨强度的影响[J].中国骨质疏松杂志,2017,23(2):227-230,247.
[11]陈建军,叶湛,杜一鑫,等.仙灵骨葆治疗骨质疏松股骨粗隆间骨折的临床疗效[J].中国老年学杂志,2015,13(19):5562-5564.
[12]冯达周,陈钢,潘京华,等.仙灵骨葆结合经皮球囊扩张椎体后凸成形术治疗老年骨质疏松椎体压缩性骨折的效果[J].广东医学,2017,38(6):959-962.
[13]史历,马峻岭,杨蕾,等.仙灵骨葆胶囊联合钙尔奇D600治疗骨质疏松症的临床研究[J].现代中西医结合杂志,2013,22(32):3552-3553.
[14]金永鑫,吕晓强,刘志英,等.仙灵骨葆胶囊联合鹿瓜多肽注射液对椎体骨质疏松的临床疗效[J].中国生化药物杂志,2017,37(3):147-149.
[15]武永娟.仙灵骨葆治疗骨质疏松症的临床疗效观察[J].临床和实验医学杂志,2013,12(18):1494-1495.
[2]张宇,李新,张红梅,等.老年骨质疏松及伴有低钠血症骨质疏松患者的临床研究[J].中华老年医学杂志,2017,36(8):872-876.
[3]张春丽,李忠海,周颖,等.构建骨质疏松动物模型建模方法的改进及评价[J].中国组织工程研究,2016,20(5):754-759.
[4]杨卫红,俞洁菲,张琼,等.老年骨质疏松患者对骨质疏松认知程度和生活质量现况调查[J].中华老年医学杂志,2015,34(11):1254-1256.
[5]付秋瑞,刘海鹏,陈高飞,等.pkp结合抗骨质疏松药治疗骨质疏松性椎体压缩骨折效果探讨[J].中国生化药物杂志,2017,25(7):233-234.
[6]徐绍俊,黄建烽,邵敏,等.雌激素受体α基因甲基化与骨质疏松关系的研究进展[J].中国骨质疏松杂志,2017,23(3):388-391.
[7]杨德鸿,胡少宇,孟越,等.特立帕肽保守治疗骨质疏松性脊柱骨折:12例报告[J].南方医科大学学报,2016,36(3):414-418.
[8]骆天红,Julie Michelle Blair,Sebastian Sorsaburu等.特立帕肽(重组人甲状旁腺素1-34)在骨质疏松治疗中的应用[J].中华内分泌代谢杂志,2013,29(12):后插3-后插9.
[9]周晓清,陈晓钢,胡小吾等.特立帕肽预防骨质疏松患者腰椎融合术后椎弓根螺钉松动的前瞻性研究[J].中国骨质疏松杂志,2014,20(3):285-287,296.
[10]谢辉.联合使用固力康和特立帕肽对去卵巢大鼠股骨干骺端骨量、骨强度的影响[J].中国骨质疏松杂志,2017,23(2):227-230,247.
[11]陈建军,叶湛,杜一鑫,等.仙灵骨葆治疗骨质疏松股骨粗隆间骨折的临床疗效[J].中国老年学杂志,2015,13(19):5562-5564.
[12]冯达周,陈钢,潘京华,等.仙灵骨葆结合经皮球囊扩张椎体后凸成形术治疗老年骨质疏松椎体压缩性骨折的效果[J].广东医学,2017,38(6):959-962.
[13]史历,马峻岭,杨蕾,等.仙灵骨葆胶囊联合钙尔奇D600治疗骨质疏松症的临床研究[J].现代中西医结合杂志,2013,22(32):3552-3553.
[14]金永鑫,吕晓强,刘志英,等.仙灵骨葆胶囊联合鹿瓜多肽注射液对椎体骨质疏松的临床疗效[J].中国生化药物杂志,2017,37(3):147-149.
[15]武永娟.仙灵骨葆治疗骨质疏松症的临床疗效观察[J].临床和实验医学杂志,2013,12(18):1494-1495.